Is USRM or JNJ a better dividend investment in 2026?

USRM currently yields 2000000.00% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: USRM offers higher current income.

What is the dividend yield difference between USRM and JNJ?

USRM has a forward dividend yield of 2000000.00% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 1999996.64 percentage points.

Home › Compare › USRM vs JNJ

USRM vs JNJ: Dividend Comparison 2026

USRM yields 2000000.00% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 USRM wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

USRM

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full USRM calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — USRM vs JNJ

📍 USRM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	USRM	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, USRM + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

USRM pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

USRM

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, USRM beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of USRM + JNJ for your $10,000?

USRM: 50%JNJ: 50%

100% JNJ50/50100% USRM

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

USRM

No analyst data

Altman Z

-3283.5

Piotroski

4/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

USRM buys

JNJ buys

No recent congressional trades found for USRM or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricUSRMJNJ

Forward yield	2000000.00% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$4.879226400974806e+39M	$20.0K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$827.78
Total dividends collected	$4.879195005460081e+39M	$5.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: USRM vs JNJ ($10,000, DRIP)

Year	USRM Portfolio	USRM Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$10,676	$355.77	+$200.00M → USRM
2	$3,738,731,768,458	$3,738,517,757,009.35	$11,407	$389.39	+$3738731.76M → USRM
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$12,198	$426.53	+$65315062866.92M → USRM
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$13,056	$467.62	+$1066400830062625.00M → USRM
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$13,987	$513.12	+$16272182796453826560.00M → USRM
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$14,998	$563.56	+$2.3205424011366188e+23M → USRM
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$16,098	$619.52	+$3.0927990661046884e+27M → USRM
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$17,295	$681.69	+$3.8524105697352695e+31M → USRM
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$18,599	$750.82	+$4.484688260147987e+35M → USRM
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$20,022	$827.78	+$4.879226400974806e+39M → USRM

USRM vs JNJ: Complete Analysis 2026

USRM — Stock

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. Its product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

Full USRM Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this USRM vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

USRM vs SCHD USRM vs JEPI USRM vs O USRM vs KO USRM vs MAIN USRM vs ABBV USRM vs MRK USRM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.